Abstracts may be submitted under one of the following nine conference tracks:

• Transdiagnostic Mental Health & Multi-morbidity of Mood and Anxiety Disorders

• Neurobiological Advances in Mood and Anxiety Disorders

• Novel Development & Pharmacological / Neuromodulation Therapies

• Socio-Cultural Dimensions and Trauma-informed Care

• Advances in Psychosocial Interventions

• Digital Mental Health & Artificial Intelligence

• Integrating Digital Tools with Traditional Care

• Upstream Solutions: Prevention & Digital Innovation

• Regulating Digital Therapeutics: Balancing Innovation and Safety

Important:

Select the most appropriate track to ensure proper evaluation. Abstract content must align with the chosen track. The Programme Committee reserves the right to reassign abstracts to more suitable tracks if necessary.

Presentation Format

Abstracts will be considered for Poster and Oral presentation. The Scientific Programme Committee will make final determinations regarding acceptance for Poster and selection for Oral presentation, considering the content and author preferences where possible.

 Language and Quality Standards

All submissions must be prepared and presented in clear, professional English with proper grammar and spelling suitable for academic publication. Authors are strongly encouraged to have their abstracts reviewed by native English speakers, institutional writing centres, or professional editors before submission. Abstracts will be published exactly as submitted. No editorial corrections will be made. Modifications are not permitted after the submission deadline.

 Ethical and Scientific Standards

• Research described must have appropriate ethical approval according to local institutional and regulatory requirements

• Abstracts must present original work not previously published or presented at other conferences prior to this Congress

• Patient identifiers, hospital identification numbers, or other personal information must not be included

• Commercial product names or brand names are prohibited; use generic drug names only

• Scientific agent or molecule references must follow standard academic publication guidelines

• Content must be balanced and free from commercial promotional material

 Conflict of Interest Declaration

To maintain educational integrity free from commercial influence, the submitting author must declare any potential conflicts of interest for all listed authors during the submission process.

 Submission Limits

Each individual may submit a maximum of 3 abstracts as presenting author. While organisers will attempt to prevent scheduling conflicts, if conflicts arise, a listed co-author must assume presentation responsibilities.

Length and Structure

Maximum length: 250 words (from introduction to conclusions). If the length exceeds the word limit, the Scientific Programme Committee reserves the right to reject the submission.

 Required Structure:

• Title (clearly indicating the nature of the research)

• Introduction

• Objectives

• Method

• Results

• Conclusions

 References and Citations

All citations must be referenced within the abstract text. Unreferenced elements will be removed before publication. Essential references should follow this format: (Smith et al. J Mood Disord 2024; 15: 123-130).

• Abstracts can be submitted through this link: BICOMH Abstract Submission

• Please submit in MS Word document file.

Abstracts undergo evaluation by the Scientific Programme Committee, Organising Committee, and expert reviewer panel. Scheduling information will be provided following acceptance notification.

• Only abstracts from authors who confirm presentation and complete registration by 31 May 2026 will be scheduled and included in the Congress Abstract e-Supplement

• Presenters will receive detailed confirmation and registration instructions via email

• The same user account must be used for both abstract submission and registration to ensure proper linking

• Abstract submission constitutes author consent for publication in the Congress Abstract e-Supplement, website, programmes, and promotional materials

• Selected oral presentation authors may be required to grant recording rights for educational purposes

• Non-compliant abstracts will be rejected

• The Scientific Programme Committee retains final authority over all acceptance decisions

Declaration: Submission requires reading and accepting the complete terms and conditions via the online submission form.

All abstract submission will be considered for Outstanding Abstract Awards.

Abstract Evaluation Criteria

To assist authors in preparing high-quality submissions, abstracts will be evaluated according to the following criteria:

•  Relevance and Significance

  The research topic must demonstrate clear relevance to the conference theme "Scientific Frontiers in Mood & Anxiety Disorders: Multimorbidity, Digital Innovation, and Therapeutic Transformation" and hold substantial importance for conference attendees and the broader scientific community working in mood and anxiety disorders.

•  Research Focus and Objectives

  Aims and research questions should be clearly articulated, appropriately focused, and directly relevant to the chosen conference track. Objectives must be sufficiently specific and achievable within the scope of the presented work, avoiding overly broad or unfocused research questions.

• Methodological Rigour

  The methodology must be appropriate for addressing the stated research objectives, scientifically sound, and clearly justified. Authors should provide sufficient detail regarding their approach, including analytical methods, to allow proper evaluation of the research design's validity and reliability. 

• Results and Data Interpretation

  Findings must align with the stated aims, be presented accurately, and demonstrate valid interpretation of the data. Results should be clearly communicated with appropriate statistical analysis where applicable, ensuring conclusions are supported by the evidence presented.

• Scientific Conclusions

  Conclusions must logically follow from the presented results and directly address the original research objectives. Authors should avoid overstating findings or drawing conclusions that extend beyond what the data supports.

• Communication Quality

  Abstracts must demonstrate scientific rigour through clear, grammatically correct writing that effectively communicates complex ideas. The structure should facilitate understanding whilst maintaining appropriate academic standards throughout.

• Innovation and Impact

  Evaluation considers the novelty of the research approach, innovative methodologies, generation of new insights, and potential impact on clinical practice, policy development, or advancement of scientific knowledge within mood and anxiety disorder research.

• Appropriateness for Academic Presentation

  The research topic and findings must be suitable for presentation at an academic conference, free from content that could raise ethical concerns, political sensitivities, or potential harm to participants or the broader community. Work involving sensitive populations or controversial topics must demonstrate appropriate ethical oversight and responsible presentation of findings.

Note: The Scientific Programme Committee reserves the right to request additional information or clarification regarding any aspect of submitted abstracts during the review process.